查看文章

The clinical efficacy of cidofovir for the treatment of adenovirus-related disease is limited, and toxicity is a major concern. Furthermore, pharmacokinetic limitations such as poor bioavailability lead to an insufficient fidelity between the prescribed dose and the pharmacodynamics effects. Nitazoxanide, an agent with broad antiviral activity and less toxicity, may be a consideration for non-life-threatening adenovirus-related enteritis/colitis. Moreover, different from the virus-targeted mechanisms of other therapies, the mechanism of nitazoxanide and tizoxanide, the active metabolite, involves the disruption of host-regulated pathways involved in viral replication (1–3). This mechanistic nuance limits the viral resistance for nitazoxanide. We present a case of an immunocompromised adult with adenovirus-related diarrhea and low-level viremia who was successfully treated with nitazoxanide. A 61-year-old patient was …